Manuel Sureda González

p>Dr. Manuel Sureda González is a clinical oncologist and pioneer in advanced immuno-oncology in Spain. He introduced personalized anti-tumor vaccines and high-dose interleukin-2 therapy before these methods became global standards. Dr. Sureda González serves as a Senior Specialist at Quironsalud Torrevieja.

Specialization and Advanced Techniques

The doctor creates personalized cancer therapies using RNA microarrays and pharmacogenomics. These tools allow him to tailor treatments to a patient's genetic profile. He treats advanced cancers using Intra-arterial and Intraoperative Chemotherapy (HIPEC). This method delivers concentrated medication directly to the tumor during surgery.

Dr. Sureda González also provides high-dose interleukin-2 therapy via intravenous bolus for solid tumors. He specializes in hyperthermic isolated limb perfusion using TNF and melphalan. Additionally, he develops personalized cellular anti-tumor vaccines for his patients. He also performs autologous bone marrow transplants and high-dose chemotherapy.

Work Experience

• 2002–present — Senior Specialist in Oncology at Quironsalud Torrevieja
• 2000–2002 — Director of the Cancer Institute at the General Hospital of Catalonia
• 1993–2002 — Director of the Hematopoietic Progenitor Transplant Program at the General Hospital of Catalonia
• 1993–2000 — Head of Medical Oncology at the General Hospital of Catalonia

Education and Academic Training

Dr. Sureda González earned his medical degree from the University of Navarra with Honors. He completed his residency at the Clínica Universidad de Navarra via the Spanish MIR system. The doctor also holds a Doctor of Medicine, Cum Laude degree from the University of Navarra.

• 1991 — Doctor of Medicine, Cum Laude, University of Navarra
• 1986–1989 — Board-Certified Specialist in Medical Oncology, Clínica Universidad de Navarra
• 1979–1985 — Medical Degree with Honors, University of Navarra
• Advanced Fellowship in Immunotherapy at the Cleveland Clinic Foundation, USA

Research and Scientific Recognition

The doctor is the author of 120+ scientific papers and conference presentations. He conducts research on novel cancer immunotherapies and drug personalization strategies. His work contributes to the development of tailored treatment protocols for complex oncological cases.

Professional Memberships

• American Association for Cancer Research (AACR)
• American Society of Clinical Oncology (ASCO)
• American Society of Hematology (ASH)